IMC Chicago’s Neurocrine Biosciences NBIX Stock Holding History

IMC Chicago’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Buy	17,000 +2,000	+13%	+$297K	﹤0.01%	2669
2026 Q1	$1.98M	Buy	15,000 +4,900	+49%	+$650K	﹤0.01%	2581
2025 Q4	$1.43M	Buy	+10,100	New	+$1.46M	﹤0.01%	2695

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IMC Chicago's NBIX Position: Q2 2026 in Review

IMC Chicago sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 4,951 shares — an estimated $735K sold.

IMC Chicago first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $652K in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

IMC Chicago reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 4,951 Neurocrine Biosciences shares in Q2 2026, an estimated $735K.
IMC Chicago first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
IMC Chicago's Neurocrine Biosciences position peaked at $652K in Q1 2026.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.